微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Lipolysis
Lipolysis

内分泌

关键词内分泌 临床研究术语 代谢

词汇介绍

拓展阅读

解析

lipolysis   英 /lɪ'pɒlɪsɪs/

释    义   n. 脂类分解;[生化] 脂解作用

例    句   The treatment is a form ofnon-invasive, laser-assisted fat-removal, or lipolysis.这是一种非侵入性、激光辅助消除脂肪或分解脂类的疗法。

概述

脂解是代谢途径,通过该脂质的甘油三酯被水解成甘油和三个脂肪酸。在禁食或运动期间它被用来调动储存的能量,通常发生在脂肪细胞中。脂肪分解是由几种激素引起的,包括胰高血糖素,肾上腺素,去甲肾上腺素,生长激素,心钠素,脑钠素和皮质醇。 病理机制 在这些区域,细胞内甘油三酸酯储存在细胞质脂质小滴中。当脂肪酶被磷酸化,通过水解的多个步骤,击穿甘油三酯分解为脂肪酸和甘油的脂滴。水解的每个步骤导致一种脂肪酸的去除。脂肪分解的第一步和限速步骤是

Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice复制标题

褪黑素通过抑制2型糖尿病小鼠脂解和肝酮体生成改善SGLT2抑制剂诱导的糖尿病酮症酸中毒

发表时间:2019-11-19

影响因子:15.2

作者: Park JH

期刊:J Pineal Res

Sodium glucose cotransporter 2 inhibitors (SGLT2i) are a new class of effective hypoglycemic agents that can be used to treat type 2 diabetes (T2D) by suppressing glucose reabsorption in the kidney. SGLT2i exert additional beneficial effects on obesity and hypertension. However, SGLT2i might raise the risk of diabetic ketoacidosis (DKA), including euglycemic DKA, and the risk of DKA is higher with SGLT2i treatment than with other glucose-lowering agents such as DPP4 inhibitors. DKA is an acute and fatal complication of diabetes and therapeutic management of DKA includes fluid replacement for electrolyte balance and insulin infusion. However, there are no clear preventive agents for DKA. Furthermore, euglycemic DKA could lead to delayed diagnosis and treatment because of the normal blood glucose level, and this can accelerate progressive metabolic deterioration. Therefore, even though the incidence of euglycemic DKA development associated with SGLT2i in T2D is low, it is important to develop a therapeutic or preventive agent for SGLT2i-induced euglycemic ketoacidosis. Mechanisms for euglycemic DKA associated SGLT2i have been proposed, including hypoinsulinemia due to decreased blood glucose levels and increases in insulin counter-regulatory hormones (glucagon, corticosterone, and growth hormone) due to reduction of insulin secretion. It has also been reported that SGLT2i can increase plasma corticosterone and catecholamine concentrations due to osmotic diuresisinduced hypovolemia. All of these systemic changes induced by SGLT2i could stimulate white adipose tissue (WAT) lipolysis and hepatic ketogenesis, resulting in euglycemic DKA. SGLT2i induce glycosuria, which can decrease blood glucose levels, resulting in euglycemic DKA. Moreover, SGLT2i can also induce mild insulin deficiency and improve insulin resistance, resulting in euglycemic DKA.

译文

钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)是一类新型的有效降糖药,可通过抑制肾脏葡萄糖再吸收来治疗2型糖尿病(T2D)。SGLT2i对肥胖和高血压有额外的有益作用。然而,SGLT2i可能会增加糖尿病酮症酸中毒(DKA)的风险,包括血糖正常的DKA,并且SGLT2i治疗DKA的风险高于其他降糖药物,如DPP4抑制剂。DKA是糖尿病的一种急性、致死性并发症,其治疗方法包括液体置换、电解质平衡和胰岛素输注。然而,目前尚无明确的预防DKA的药物。此外,血糖正常的DKA可导致延迟诊断和治疗,从而加速进行性代谢恶化。因此,尽管在T2D中与SGLT2i相关的正常血糖DKA发生率较低,但开发一种治疗或预防SGLT2i诱导的正常血糖酮症酸中毒的药物是非常重要的。已经提出了血糖正常的DKA相关的SGLT2i的机制,包括血糖水平降低引起的低胰岛素血症和胰岛素分泌减少引起的胰岛素反调节激素(胰高血糖素、皮质酮和生长激素)增加。另据报道,SGLT2i可增加血浆皮质酮和儿茶酚胺浓度,这是由于渗透性利尿剂引起的低血容量。所有这些由SGLT2i引起的系统性改变都能刺激白脂肪组织(WAT)的脂解和肝酮生成,导致DKA的血糖正常。SGLT2i引起糖尿,可降低血糖水平,导致血糖正常的DKA。此外,SGLT2i还可诱导轻度胰岛素缺乏,改善胰岛素抵抗,导致血糖正常的DKA。